Anteris Posts Q3 2025 Results, Secures Key Approvals for PARADIGM Trial Launch

Anteris Technologies reported Q3 2025 financial results, with net operating cash outflows of $59.3 million. R&D expenses reached $16.8 million, driven by IDE-related work and manufacturing upscaling. Selling, general & administrative expenses were $5.8 million. Cash and cash equivalents stood at $9.1 million. The company secured key approvals to launch the PARADIGM trial of the DurAVR transcatheter heart valve, including FDA approval in the US and Danish approval in Europe.